{
    "clinical_study": {
        "@rank": "122679", 
        "arm_group": [
            {
                "arm_group_label": "Lesinurad 400 mg and naproxen 250 mg", 
                "arm_group_type": "Experimental", 
                "description": "Lesinurad once daily (qd) Day 1, naproxen twice daily (bid) Day 2-6, lesinurad qd with naproxen bid Day 7-14."
            }, 
            {
                "arm_group_label": "Lesinurad 400 mg and indomethacin 25 mg", 
                "arm_group_type": "Active Comparator", 
                "description": "Lesinurad qd Day 1, indomethacin bid Day 2-6, lesinurad qd with indomethacin bid Day 7-14."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a drug-drug interaction study in healthy volunteers to evaluate the potential\n      pharmacokinetic (PK) effects of non-steroidal anti-inflammatory drugs on lesinurad and\n      leinurad on the non-steroidal anti-inflammatory drugs."
        }, 
        "brief_title": "NSAID Drug Interaction Study", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": "Gout", 
        "detailed_description": {
            "textblock": "Naproxen and indomethacin are non-steroidal anti-inflammatory drugs (NSAIDs) used both\n      prophylactically for the prevention of, and as a treatment for, acute gout flares.\n      RDEA594-126 is an open-label study designed to assess the potential effect of multiple doses\n      of naproxen and indomethacin on the single-dose PK of lesinurad, and to assess the potential\n      effect of multiple doses of lesinurad on the multiple-dose PK of naproxen and indomethacin."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject has a body weight \u2265 50 kg (110 lbs) and a body mass index (BMI) \u2265 18 and \u2264 30\n             kg/m2.\n\n          -  Subject is free of any clinically significant disease that requires a physician's\n             care and/or would interfere with study evaluations or procedures.\n\n          -  Subject has no clinically relevant abnormalities in vital signs, ECG, physical\n             examination or safety laboratory values.\n\n        Exclusion Criteria:\n\n          -  Subject has clinically significant pulmonary, cardiovascular, gastrointestinal,\n             neurologic, hepatic, renal, urological, or psychiatric disorders.\n\n          -  Subject has a history or suspicion of kidney stones.\n\n          -  Subject has a history of asthma.\n\n          -  Subject has undergone major surgery within 3 months prior to Day 1.\n\n          -  Subject has donated blood or experienced significant blood loss (> 450 mL) within 12\n             weeks prior to Day 1 or gave a plasma donation within 4 weeks prior to the Screening\n             visit.\n\n          -  Subject has inadequate venous access or unsuitable veins for repeated venipuncture."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01884272", 
            "org_study_id": "RDEA594-126"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Lesinurad 400 mg and naproxen 250 mg", 
                    "Lesinurad 400 mg and indomethacin 25 mg"
                ], 
                "intervention_name": "lesinurad 400 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Lesinurad 400 mg and naproxen 250 mg", 
                "intervention_name": "naproxen 250 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Lesinurad 400 mg and indomethacin 25 mg", 
                "intervention_name": "indomethacin 25 mg", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Naproxen", 
                "Indomethacin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "November 6, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Kalamazoo", 
                    "country": "United States", 
                    "state": "Michigan", 
                    "zip": "49007"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1 Study to Evaluate the Potential Two-Way Pharmacokinetic Interaction Between Lesinurad and Naproxen and Between Lesinurad and Indomethacin in Healthy Adult Male Subjects", 
        "overall_official": {
            "affiliation": "Ardea Biosciences, Inc.", 
            "last_name": "S Bradley, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Profile in terms of AUC, Tmax, Cmax, and t1/2 AUC: area under the plasma concentration versus time curve; Tmax: time to maximum plasma concentration; Cmax: maximum plasma drug concentration; t1/2: apparent terminal half-life", 
                "measure": "PK profile of lesinurad from plasma and urine", 
                "safety_issue": "No", 
                "time_frame": "Day 1, Day 6 (urine only), Day 7, Day 14"
            }, 
            {
                "description": "Profile in terms of AUC, Tmax, Cmax, and t1/2", 
                "measure": "PK profile of naproxen and indomethacin from plasma and urine", 
                "safety_issue": "No", 
                "time_frame": "Day 1, Day 6 (urine only), Day 7, Day 14"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01884272"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Incidence of Adverse Events and Changes in Laboratory, Electrocardiogram, and Vital Signs Parameters", 
            "safety_issue": "Yes", 
            "time_frame": "13 weeks"
        }, 
        "source": "Ardea Biosciences, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ardea Biosciences, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}